UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) August 16, 2004
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
-----------------
--------------------------------------------------------------------------------
Nevada 000-49616 88-0488686
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification No.)
--------------------------------------------------------------------------------
11588 Sorrento Valley Road, Suite 17
San Diego, California 92121
(Address of principal executive offices) (Zip Code)
--------------------------------------------------------------------------------
Registrant's telephone number, including area code (858) 794-8889
--------------
Not Applicable
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
On August 16, 2004, Halozyme Therapeutics, Inc. issued a press release
announcing the signing of an exclusive sales and marketing agreement with Baxter
Healthcare Corporation for Enhance SC(TM). This press release is attached as
Exhibit 99.1
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
Exhibit No. Description
99.1 Press Release dated August 16, 2004 (sales and marketing
agreement).
99.2 Press Release dated August 16, 2004 (financial results).
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 16, 2004, Halozyme Therapeutics, Inc. issued a press release to report
its financial results for the three and six months ended June 30, 2004. The
press release is attached as Exhibit 99.2, which is furnished under Item 12 of
this report and shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act,
regardless of any general incorporation language in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
HALOZYME THERAPEUTICS, INC.
Date: August 16, 2004 By: /s/ David A. Ramsay
------------------------------------------
Vice President and Chief Financial Officer